BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 23350713)

  • 1. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.
    Murphy CC; Hofstetter WL; Correa AM; Ajani JA; Komaki RU; Swisher SG
    Dis Esophagus; 2013; 26(7):708-15. PubMed ID: 23350713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
    Shaikh T; Churilla TM; Monpara P; Scott WJ; Cohen SJ; Meyer JE
    Pract Radiat Oncol; 2016; 6(6):388-394. PubMed ID: 27025161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in survival after trimodality therapy for esophageal adenocarcinoma.
    Eng OS; Nelson RA; Konstantinidis I; Chao J; Erhunmwunsee L; Raz DJ; Kim JY
    Dis Esophagus; 2018 Sep; 31(9):. PubMed ID: 29534155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
    Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma.
    Murphy CC; Correa AM; Ajani JA; Komaki RU; Welsh JW; Swisher SG; Hofstetter WL
    J Gastrointest Surg; 2013 Aug; 17(8):1359-69. PubMed ID: 23715646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of patient selection, disease progression, and adverse events on esophageal cancer outcomes after trimodality therapy.
    Gilbert S; Gresham GK; Jonker DJ; Seely AJ; Maziak DE; Shamji FM; Pantarotto J; Sundaresan S
    Ann Thorac Surg; 2012 Nov; 94(5):1659-66. PubMed ID: 22981444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
    Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
    Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer.
    Shaikh T; Meyer JE; Horwitz EM
    Surg Oncol Clin N Am; 2017 Jul; 26(3):405-429. PubMed ID: 28576180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.
    Kesler KA; Helft PR; Werner EA; Jain NP; Brooks JA; DeWitt JM; Leblanc JK; Fineberg NS; Einhorn LH; Brown JW
    Ann Thorac Surg; 2005 Apr; 79(4):1116-21. PubMed ID: 15797035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
    Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
    J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.
    Yang GQ; Mhaskar R; Rishi A; Naghavi AO; Frakes JM; Almhanna K; Fontaine J; Pimiento JM; Hoffe SE
    Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 30597022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
    Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
    Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.
    Taketa T; Correa AM; Suzuki A; Blum MA; Chien P; Lee JH; Welsh J; Lin SH; Maru DM; Erasmus JJ; Bhutani MS; Weston B; Rice DC; Vaporciyan AA; Hofstetter WL; Swisher SG; Ajani JA
    Oncology; 2012; 83(5):300-4. PubMed ID: 22964903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
    Hayashi Y; Xiao L; Suzuki A; Blum MA; Sabloff B; Taketa T; Maru DM; Welsh J; Lin SH; Weston B; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Ajani JA
    Eur J Cancer; 2012 Dec; 48(18):3396-404. PubMed ID: 22853875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate lymph node assessment prior to trimodality therapy for esophageal carcinoma.
    Suntharalingam M; Haas ML; Sonett JR; Doyle LA; Hausner PF; Schuetz J; Greenwald B; Krasna MJ
    Cancer J; 2001; 7(6):509-15. PubMed ID: 11769864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.